GlassScriptPhysician profile
Michael W Fong
NPI 1407863756
$9,366.75
in general payments reported to CMS, 2019-2025
23 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $66.50 · 2021: $113 · 2022: $333 · 2023: $414 · 2024: $6,304 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,938 · Food and Beverage: $1,354 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,937.50 |
| Food and Beverage | $1,353.56 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $6,087.38 | 2023-2024 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $1,311.95 | 2023-2025 | Optimizer, Optimizer |
| Abbott Laboratories | $550.70 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic Vascular, INC. | $313.38 | 2019 | |
| Ancora Heart, INC. | $263.32 | 2025 | Accucinch |
| Boston Scientific Corporation | $162.99 | 2019 | |
| Shockwave Medical, INC | $143.91 | 2025 | |
| Edwards Lifesciences Corporation | $129.36 | 2024 | |
| Novo Nordisk INC | $96.81 | 2021-2024 | Wegovy |
| Akcea Therapeutics, INC. | $66.50 | 2020 | |
| Abiomed | $63.96 | 2022 | |
| Medtronic, INC. | $37.03 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.86 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $24.61 | 2024 | Wainua |
| Merck Sharp & Dohme LLC | $21.70 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $21.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.14 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.06 | 2024 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.07 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.